Silencing of the von Willebrand factor gene in proatherothrombotic APOE∗3-Leiden.CETP transgenic mice
Open Access
- 6 February 2025
- journal article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (1) , 102699
Abstract
No abstract availableKeywords
Funding Information
- Türk Nefroloji Dernegi
- CSL Behring
- Trombosestichting Nederland (2018-01)
This publication has 45 references indexed in Scilit:
- Impact of allele-selective silencing of von Willebrand factor in mice based on a single nucleotide allelic difference in von Willebrand factorThrombosis Research, 2024
- Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and GuidelinesCurrent Neurology and Neuroscience Reports, 2023
- The Extent to Which Lipid Nanoparticles Require Apolipoprotein E and Low-Density Lipoprotein Receptor for Delivery Changes with Ionizable Lipid StructureNano Letters, 2022
- siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticlesJournal of Controlled Release, 2022
- Lower levels of vWF are associated with lower risk of cardiovascular diseaseResearch and Practice in Thrombosis and Haemostasis, 2022
- Choline and butyrate beneficially modulate the gut microbiome without affecting atherosclerosis in APOE*3-Leiden.CETP miceAtherosclerosis, 2022
- The Effects of Hyperglycemia on Early Endothelial Activation and the Initiation of AtherosclerosisThe American Journal of Pathology, 2022
- Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic miceJournal of Thrombosis and Thrombolysis, 2021
- Nanotechnology for In vivo Targeted siRNA Delivery2014
- RNA interference for therapy in the vascular endotheliumMicrovascular Research, 2010